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INTRODUCTION
Low back pain (LBP) is a pervasive problem impacting health systems across the world. 
In the United States, chronic LBP impacts up to 40% of Americans and results in exces-
sive financial strain on the healthcare budget, estimated at up to $100 billion annually.1 
Furthermore, treatment results are often disappointing, with the traditional pathway of 
conservative measures, narcotic pain medication, and surgical decompression and/or 
fusion leading to both patient and provider frustration, complications, and diminished 
patient productivity and quality of life. This has naturally led to questions from policy-
makers regarding the utility of healthcare dollars spent on back pain. In this milieu, a 
variety of neuromodulation techniques have found a niche in the management of this 
patient population, with indications commonly quoted including failed back surgery 
syndrome (FBSS), chronic neuropathic pain, and complex regional pain syndrome 
(CRPS), among others.1,2 From its inception on the basis of Melzak and Wall’s gate 
theory³, to its first human trial in the 1960s,⁴ and to the modern era, spinal cord 
stimulation has undergone a series of innovations that have expanded indications and 
improved patient outcomes. The goal of this study is to summarize the most important 
clinical trials involving both traditional SCS and newer stimulation paradigms to provide 
an overview of the current state of affairs of this rapidly-growing field.
METHODS
We performed a PubMed literature search utilizing the following terms: SCS, spinal 
cord stimulation, neuromodulation, high frequency stimulation, paresthesia free, 
HF10, failed back surgery syndrome, and chronic pain. Only English language articles 
were reviewed. All prospective, randomized controlled trials pertaining to the use of 
neuromodulation in the treatment of chronic back and limb pain were included. The 
data extraction was performed by three reviewers (JT, JH, CH), and reviewed by the 
senior author (CW). The selected studies were analyzed, and relevant results were 
summarized as follows.
RESULTS
Traditional, Low Frequency, Tonic SCS
Several landmark trials paved the way for the widespread use of spinal cord stimula-
tion in the treatment of chronic back and limb pain. These early studies utilized low 
frequency stimulation generally in the 40-100 Hz range delivered in a tonic manner, 
producing paresthesias that overlap the areas where the patient experiences pain. 
North et al5 randomized 51 FBSS patients with chronic lower limb pain with or without 
back pain to initial treatment with a low frequency stimulator or re-operation. The 
primary endpoint was “success”, defined as > 50% reported pain relief and patient 
satisfaction with treatment at 2-years post-operatively or at last follow-up. Secondary 
end points included treatment crossover, success at last follow-up, and improve-
ment in medication use, daily activities, and neurologic status. At mean three-year 
follow-up, “success” was achieved in a significantly higher proportion of patients 
randomized to SCS (47%) compared to 
those randomized to reoperation.5,6 
These findings remained statistically 
significant even after worst-case analysis 
which assumed patients unavailable for 
long-term follow-up in the SCS group 
were all treatment failures. Further, a 
significantly higher proportion of patients 
in the reoperation arm crossed over to 
SCS (54%) compared to only 21% of SCS 
patients who elected to undergo reop-
eration. While patient reported functional 
capacity didn’t reach a significant differ-
ence, SCS patients did require significantly 
fewer opiate equivalents for pain control. 
Kumar et al 7,8 followed this up with the 
PROCESS study which randomized 100 
FBSS patients with limb>back pain to 
SCS with medical management (n=52) 
or medical management alone (n=48). 
The primary end point of the study was 
defined as > 50% relief of leg pain, with 
secondary end points including quality 
of life, functional capacity as measured 
by the Oswestry Disability Index (ODI), 
patient satisfaction, and changes in pain 
medication usage. At 6-month follow-
up, the primary endpoint was achieved in 
48% of SCS patients compared to 9% in 
the medical management alone group. 
The SCS group also reported significantly 
greater quality of life, improvement in ODI, 
treatment satisfaction, and reduced back 
pain compared to medical management 
alone. SCS patients were also more likely 
to reduce drug intake based on morphine 
equivalents as well as decrease use of non-
drug therapies. Similar improvements were 
maintained at 12 and 24 month follow-up 
analyses.7,8
Paresthesia-Free SCS
As clinical experience with traditional, 
paresthesia-based systems grew, interest 
began to develop in creating new stimu-
lation protocols that would generate 
pain relief without the need for pares-
thesia overlap as a significant number 
of patients found these sensations to be 
uncomfortable, particularly when there 
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pain compared to baseline, higher likeli-
hood of achieving minimal disability on 
ODI, and higher patient reported treat-
ment satisfaction. Additionally, 11.3% 
of patients in the tSCS group reported 
uncomfortable paresthesias, with no 
patients in the HF10 group reporting any 
paresthesia-related issues.14,15
Despite accumulating clinical evidence 
regarding the efficacy of high frequency 
SCS, several questions remained. One such 
issue is the impact of varying frequencies 
and other stimulation parameters on treat-
ment effect. One study16 prospectively 
randomized a cohort of 24 patients into a 
blinded crossover study, with each patient 
experiencing 3 weeks at a time of sham 
stimulation, and stimulation at 1200 Hz, 
3030 Hz, and 5882 Hz. The devices were 
programmed such that amplitude was 
maintained slightly below threshold level, 
unique to each patient and frequency. 
The primary outcome was the reduction 
of VAS back pain scores. Baseline VAS 
was reported at 7.75, with improvement 
to 4.83, 4.51, 4.57, and 3.22 for the trial 
groups (sham, 1200 Hz, 3030 Hz, and 
5882 Hz, respectively). All comparisons 
to baseline were significant, but within 
the treatment groups only 5882 Hz had a 
significantly greater impact on outcome. 
The authors argued that while designed 
as a study on frequency, the impact of 
pulse width on allowable amplitude 
without generating paresthesia yielded 
higher charger-per-second dosing with 
higher frequency stimulation, which 
may have played a role in the results. 
The results also questioned to what 
degree pain relief afforded by spinal cord 
stimulation is a result of placebo, as at 
the end of the study 12.5% of patients 
preferred the sham stimulation protocol. 
A similar study also explored the impact 
of varying degrees of high-frequency 
stimulation on treatment effect, noting 
the unclear mechanism of HF10 and the 
unclear impact of frequency on clinical 
outcome. In this study, Thomson et al 17 
randomized 21 patients with chronic 
back>leg pain who had passed a trial of 
10 kHz stimulation and were implanted 
with permanent devices. Each patient 
experienced four weeks of stimulation, 
in random order, at 10 kHz, as well as 1-, 
4-, and 7 kHz. At each frequency, pulse 
width and amplitude were adjusted to 
optimize therapy. The impact on the 
patients reverted to their traditional, 
paresthesia-based pattern. The primary 
outcome was the Patient’s Global 
Impression of Change (PGIC), with 
secondary outcomes including VAS 
and the Euroqol questionnaire EQ-5D. 
At the end of the study, the authors 
noted no difference between sham and 
high-frequency stimulation, with what 
appeared to be a “period effect” in that 
patients tended to respond more favor-
ably to sham or 5 kHz stimulation based 
purely on which was initiated first and 
responded less favorably to whichever 
pattern was tested second. However, 
the comparison to baseline values is 
confusing and again the use of previously 
stabilized tSCS patients is a variable that 
must be considered. The most robust 
data in this field came from Kapural and 
colleagues who explored the ability of 
low amplitude, high frequency spinal 
cord stimulation at 10 kHz to provide 
durable relief of both axial and appen-
dicular pain in the SENZA trial.14,15 In this 
prospective, multicenter, randomized trial, 
the investigators randomized 198 patients 
with medically refractory back and leg 
pain to either high frequency stimula-
tion (HF10) or traditional low frequency, 
paresthesia-dependent treatment (tSCS). 
The primary endpoint was >50% reduc-
tion on the visual analog scale (VAS), with 
secondary outcomes including opioid 
use, functional disability as measured by 
ODI, and percentage change from base-
line back and leg symptoms. A total of 
171 patients had positive trials and were 
ultimately implanted (HF10, n=90; tSCS, 
n = 81). At the initial 3-month evalua-
tion, 84.5% of HF10 patients achieved 
the primary endpoint for back pain, 
compared to only 43.8% of tSCS patients. 
Similarly, for leg pain HF10 success on the 
primary endpoint was 83.1% compared 
to 55.5% for tSCS. These values remained 
similar at 12-month follow-up evalua-
tion, with remission rates (VAS <2.5) for 
back and leg pain approaching 67% for 
HF10, compared to 35-40% for tSCS. 
At 24-month evaluation, the difference 
in primary endpoint success was still 
maintained in favor of HF10 for both 
back and leg pain (76.5% and 72.9% 
respectively for HF10, compared to ~50% 
for tSCS). Secondary outcome analysis 
also favored HF10, with greater overall 
percentage reduction of back and leg 
is significant postural variation which 
can make certain daily activities, such 
as driving, difficult or painful. Further-
more, traditional spinal cord stimulation, 
while relatively successful at treating 
appendicular neuropathic symptoms, 
struggled with relief of more nociceptive 
axial pain where adequate paresthesia 
overlap is difficult to achieve. Given how 
common low back pain is in the general 
population, a more efficient means for 
targeting this symptom complex was 
needed. Buyten et al 9 prospectively 
enrolled 82 patients with back pain with 
or without associated leg pain in a trial 
of high frequency, low amplitude, pares-
thesia free stimulation using the Nevro 
device. The outcomes of interest were 
VAS scores, ODI, sleep disturbances per 
night, and patient satisfaction. The trial 
to conversion rate was 88%. VAS back 
and leg scores improved at 6 months, 8.4 
to 2.7 for back and 5.4 to 1.4 for leg pain. 
ODI improved by 17 points and patients 
reported 2.4 fewer episodes of sleep 
disturbance per night. Similar results 
were obtained with HF10 therapy in 
another prospective observational study 
in patients with a primary complaint low 
back pain, with back pain and leg pain 
reduced by 61% and 58%, respectively, 
based on VAS10. While promising, these 
and other observational studies did not 
provide a control group to compare 
against. To that end, De Andres et al11 
compared high frequency (10 kHz) 
stimulation to conventional stimulation, 
randomizing 55 patients with FBSS with 
neuropathic back or leg pain. The results 
suggested no significant difference at 
one year, with both stimulation profiles 
showing significant benefit compared 
to baseline values.11 On the other hand, 
North et al,12 in their pilot study random-
izing patients with FBSS who had a 
previously implanted, paresthesia-based 
system with inadequate pain relief, noted 
that pain relief via NRS and disability 
via ODI were significantly improved 
with 1 kHz stimulation.12 Perruchoud 
and colleagues13 similarly random-
ized patients with chronic neuropathic 
back and leg pain, previously stable on 
a conventional SCS system, to periods 
of sham and 5 kHz, subthreshold tonic 
stimulation. The periods of sham and 
5 kHz stimulation were separated by 
a “washout” period during which the 
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with burst compared to only 2.7% of 
tSCS patients. While 78.1% of patients 
were satisfied overall with both stimula-
tion methods, 70.8% reported preferring 
burst stimulation with lack of paresthesia 
being the most common reason cited. 
This preference was maintained at one-
year follow-up with 68.2% of patients 
continuing to prefer burst therapy. Much 
like high frequency stimulation, as the 
clinical efficacy became clear, more ques-
tions emerged regarding mechanisms and 
the impact of various stimulation param-
eters. One study  21 randomized 15 patients 
previously implanted with a burst-capable 
device in the setting of FBSS to one of two 
stimulation patterns: 1) 5 pulses delivered 
at 500 Hz with a 1000 µsec pulse width, 40 
times per second or 2) 5 pulses delivered at 
1000 Hz, 1000 µsec pulse width, 40 times 
per second. The amplitude, and thus the 
total electrical dose delivered remained 
the same. Clinical outcomes were not 
significantly different.
DISCUSSION
Spinal cord stimulation was first put 
into clinical practice in the 1960s for 
an attempt at palliation in a patient with 
terminal cancer pain.4 The momentum 
behind its initial development was 
the ubiquitous Gate Control Theory 
put forth by Melzack and Wall.3 While 
generally accepted that this theory is 
overly simplistic regarding the mecha-
nism of action in the various spinal 
cord stimulation techniques, it did 
inspire generations of physicians and 
scientists to develop new means of 
tackling medically refractory chronic 
pain syndromes.22 Traditional, low-
frequency, suprathreshold tonic spinal 
cord stimulation has been postulated 
to work via several mechanisms. Most 
commonly cited includes selective 
activation of large, myelinated Aβ fibers 
with subsequent inhibition of smaller, 
pain-mediating Aδ and c fibers via 
inhibitory interneurons. Other postu-
lated contributors include dorsal horn 
wide dynamic range neurons, thought to 
develop a hypersensitivity in neuropathic 
injury states with resultant increased 
basal glutamate release and subsequent 
glutamate:GABA imbalance. Supraspinal 
mechanisms are also thought to be at 
play although the exact brainstem-spinal 
pain was significantly reduced with burst 
therapy (-4.5 VAS) compared to tSCS 
(-2.5). Regarding the PVAQ, tonic and 
placebo stimulation showed no impact 
on attention to pain or attention to 
changes in pain, whereas burst stimulation 
significantly improved these parameters, 
suggesting an impact on affective and 
attentional components of pain. Schu et al 
19 compared high frequency stimulation to 
a burst protocol, randomizing 20 patients 
with FBSS and a previously implanted, 
burst-capable system to separate, one 
week periods of placebo stimulation, 500 
Hz tonic stimulation, and burst stimulation 
(5 pulses at 500 Hz, delivered 40 times 
per second), with the primary outcome 
of interest the impact on the numerical 
rating scale (NRS) for pain intensity. Base-
line values were obtained prior to entering 
the protocol, with the device programmed 
for standard, paresthesia-based stimula-
tion. While burst stimulation was the only 
pattern to significantly reduce the NRS 
score, the magnitude of the treatment 
effect was modest (5.6 at baseline, 4.7 
for burst stimulation), and disability as 
measured by ODI showed only a non-
significant decrease. However, it is worth 
reiterating that the “control” values in this 
study were based on patients stabilized 
on a paresthesia-based system, and thus 
treatment effects can be expected to be 
blunted, and the fact that at the end of 
the trial 80% of the patients preferred the 
burst protocol is also significant. More 
recently, Deer et al20 published results of 
the SUNBURST trial, which randomized 
patients with refractory back and leg pain 
to tSCS or burst stimulation. The trial was 
conducted in two phases. First patients 
were randomized to a 12-week period of 
a given stimulation treatment, and then 
switched to the other stimulation method 
for the next 12 weeks. Thereafter, the 
patients were allowed to choose their 
preferred stimulation method and were 
assessed every 6 months for two years. 
The primary endpoint was change in VAS. 
A total of 100 patients were randomized, 
with 45 entering tSCS first followed 
by burst, and 55 vice versa. At 12- and 
24-week analyses, both non-inferiority 
and superiority of burst stimulation as 
compared to tSCS were established via 
the primary endpoint of VAS reduction. 
Secondary endpoint analyses revealed that 
61.6% of patients were paresthesia-free 
primary outcome, NRS for back, leg, and 
overall pain, was similar between groups 
with all frequency groups showing about 
50% reduction in each category. There 
were no between-group differences. 
There was significantly less charge 
delivered in the 1 kHz stimulation than in 
the other three groups. Interestingly, the 
calculated charge delivered per second 
showed a non-linear relationship with 
frequency, suggesting that frequency 
modification in isolation may not deliver 
appropriate symptom relief, highlighting 
the importance of the interplay between 
frequency, pulse width, and amplitude.
As interest in paresthesia-free stimulation 
grows, other investigators are exploring 
novel stimulation protocols. Burst stimula-
tion, a technique based on short intervals 
of high-frequency, low amplitude stimula-
tion followed by periods of inactivity, is one 
such protocol thought to work in at least 
two mechanisms: 1) more closely mimic 
neuronal firing in the central nervous 
system with impacts on higher-order thal-
amo-cingulate pathways, and 2) provide 
inhibition of Aδ and c fibers via subthreshold 
antidromic Aβ activation with resultant 
activation of inhibitory interneurons. De 
Ridder et al18 performed an early trial with 
this technology, randomizing 15 patients 
undergoing a trial of spinal cord stimulation 
to 7 days each of burst, tonic, and sham 
stimulation. Primary endpoints included 
VAS for back, limb, and general pain, with 
secondary endpoints including the pain 
vigilance and awareness scale (PVAQ), and 
worst/best pain levels during a given trial 
week. They noted that burst stimulation 
did not induce more paresthesias than 
sham stimulation. The primary outcome 
measure showed significant improve-
ments in back, limb, and general pain 
comparing burst stimulation to placebo. 
Because burst stimulation produced no 
noticeable paresthesias, this marked the 
first time in a randomized trial that spinal 
cord stimulation could be proven better 
than control/sham treatment, an important 
landmark in SCS research. Not surprisingly, 
tSCS showed significant improvement in 
limb and general pain, but not back pain, 
compared to placebo. Comparing burst 
to tSCS, the mean change in back pain 
favored burst (-3.8 on VAS compared to 
-2.2), but this did not reach significance. 
Limb pain between the two protocols 
was the same (both -3.9 on VAS). General 
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CONCLUSION
Chronic back pain remains a highly prev-
alent clinical problem in modern society. 
This patient population has historically 
been very challenging to treat.  Spinal 
cord stimulation has helped to bridge 
the treatment gap in these patients, and 
while progress so far has been encour-
aging, there remains much research to 
be done to fully understand the mecha-
nisms and potential therapeutic reach of 
this modality.
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frustrating patient population. Medical 
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rates of narcotic medication use with 
their associated complications. Futile 
treatment regimens, although inex-
pensive in isolation, become expensive 
when applied indefinitely, and costly 
revision surgeries without clearly rectifi-
able structural or compressive pathology 
are not only low yield, but very expensive 
and potentially dangerous. Spinal cord 
stimulation has provided an opportunity 
to attain symptom relief, limit disability, 
and improve patient productivity. And 
although the upfront investment is 
large, there is an increasing amount of 
evidence suggesting that the long-term 
cost-effectiveness profile is positive 
and that spinal cord stimulation should 
be considered earlier in the broader 
treatment paradigm for chronic pain.1,2 
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